Merck Serono Jobs Profile

 

This profile is a brief introduction for people seeking employment in pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, or pharmaceutical clinical research associates who may be considering working for Merck Serono. 

Company Overview

Merck Group
The Merck Group is a global pharmaceutical and chemical company. In 2005, Merck Group sales totalled 5,870 million. Adjusted for the disposal of VWR in the second quarter of 2004, this represents an increase of 9.9% over 2004. We increased our research and development spending, which has already been substantial for a number of years, by 19% to 713 million. The operating result rose by a favorable 14% to 883 million; return on sales (ROS) was 15.0% and return on capital employed (ROCE) reached a notable 20.5%.

        

Pharmaceuticals
Our Pharmaceuticals business sector comprises not only patented drugs, but also ­generics and consumer health care products. Sales increased by 13% to 3,894 million and the operating result rose 16% to 454 million. Research and development spending grew 18% to 579 million. In the Ethicals division, we invested 442 million or 26% of the division's sales in R&D, focusing on our development compounds for oncology.

 

 

 

 

 



Claire
Merck Serono Account Manager
0844 980 8644
(Mon to Fri 0830 to 1800 hours)
claireh@zenopa.com



Current Jobs

Regional Development Manager
Location: Lancashire

Medical Scientific Liaison
Location: North UK

News

Merck Serono and Flamel confirm Medusa partnership
Merck Serono, a division of Merck KGaA, and Flamel Technologies have confirmed they are to collaborate in the development of Flamel's Medusa technology.

Merck Serono pledges support for Michael J Fox Foundation
Merck Serono has announced that it is to fund a $2 million (979,000 pounds) initiative for research into therapies to alleviate Parkinson's disease-related cognitive dysfunction and mood disorders.

Merck Serono initiates atacicept trial
Merck Serono and ZymoGenetics have announced that a new phase II/III clinical trial will be launched investigating the safety and efficacy of atacicept in patients with lupus nephritis.

Merck Serono confirms EU approval for Cyanokit
Merck Serono, a division of Merck KGaA, has confirmed that its product Cyanokit has been granted marketing authorisation by the European commission.

Merck Serono initiates Parkinson's trial
Merck Serono and its partner Newron Pharmaceuticals have initiated their Motion study which comprises of a new Phase III clinical trial of Safinamide in Parkinson's disease.


home | our clients | browse news | browse jobs | hotel directory | copyright © 2008 Zenopa Ltd | terms & conditions of use